Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08RJY
|
|||
| Drug Name |
Anti-EGFRvIII CAR transduced PBL
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Phase 1/2 | [1] | |
| Malignant glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1/2 | [1] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1/2 | [1] | ||
| Company |
National Cancer Institute (NCI)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epidermal growth factor receptor variant III (EGFR vIII) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.